Efficacy And Safety Of Domestic And Original Bortezomib In The Treatment Of Newly Diagnosed Multiple Myeloma

Objective To observe the efficacy and safety of domestic and original bortezomib in patients newly diagnosed with multiple myeloma,and to provide reference for the selection of drugs used in clinical treatment.Methods A retrospective analysis was performed on 67 patients with newly diagnosed multiple myeloma admitted to our hospital from January 2018 to February 2021.Among them,30 cases were treated with domestic bortezomib（Xintai）and 37 cases with original bortezomib（Wanke）.All of the patients with boron for m solution treatment,through the application of two groups of patients were compared after 2,4,6,8 total effective rate（overall response rate,ORR）,or very good partial response（very good partial remission,VGPR）rate,complete response（complete remission,CR）rate difference,revision of the different international staging system(revised international staging system,Riss stage,ORR,≥VGPR rate,CR rate of different age groups,and drug-related side effects of the two groups were investigated to investigate the efficacy and safety of domestic bortezomib（Xintai）and original bortezomib（Wancke）in the treatment of newly diagnosed multiple myeloma patients.Results There was no statistically significant difference in baseline values between the domestic group and the original research group.In terms of effectiveness,there were no statistically significant differences in ORR,≥ VGPR rate and CR rate between the domestic group and the original research group after 2,4 and 6 courses of borteomib regimen（P > 0.05）.The efficacy of the domestic group and the original research group after 2 courses was compared（ORR: 83.33% vs 83.78%;≥ VGPR: 56.67% vs51.35%;CR rate: 43.33% vs 24.32%）.Comparison of efficacy after 4 courses of treatment（ORR: 92.00% vs 95.00%;≥VGPR: 72.00% VS 75.00%;CR rate: 52.00% vs45.00%）,and efficacy comparison after 6 courses of treatment（ORR: 87.50% vs90.00%;≥VGPR: 81.25% vs 80.00%;CR rate: 62.50% vs 50.00%）.There was also no significant difference in efficacy between domestic borteomib group and original borteomib group in different risk stratification（P > 0.05）.After 2 courses of treatment,the efficacy of domestic and original borteomib group in high-risk group（ORR: 70.00%vs 92.86%;≥VGPR: 60.00% vs 57.14%;CR rate: 10.00% vs 21.43%）,the efficacy of the low-risk group（ORR: 86.67% vs76.47%;≥ VGPR: 53.33% vs 41.18%;CR rate:13.33% vs 17.65%）.There was also no significant difference in efficacy between domestic borteomib group and original borteomib group in different age groups（P BBB0 0.05）.After 2 courses of treatment,the efficacy of domestic group and original borteomib group ≤ 65 group（ORR: 75.00% vs 84.21%;≥ VGPR: 50.00% vs47.37%;CR rate: 20.00% vs 15.79%）,the efficacy of > 65 group（ORR: 100% vs77.78%;≥VGPR: 70.00% VS 50.00%;CR rate: 10.00% vs 27.78%）.In terms of safety,there was no significant difference between the two groups（P BBB 0 0.05）.Hematological toxicity showed thrombocytopenia rate（6.67% VS 2.70%）,neutropenia rate（10.00% VS 2.70%）,peripheral neuropathy rate（23.33% VS 37.84%）in the domestic group and the original study group.The incidence of pulmonary infection（23.33% VS 27.03%）,cardiac toxicity（20.00% VS 24.32%）,digestive tract reaction（6.67% VS 21.62%）,herpes zoster（3.33% VS 10.81%）,Rash incidence（0% VS5.40%）,thrombus incidence（0% VS 2.70%）.In terms of health economics,the domestic bortezomib group had a lower cost-effectiveness ratio,which was significantly different from that of the original bortezomib group（P < 0.05）.Conclusion There was no significant difference in efficacy between domestic and original bortezomib in the treatment of newly diagnosed multiple myeloma,and the safety of the two drugs was similar.However,the price of domestic bortezomib is relatively low,which is economical and suitable for multiple myeloma patients.